Adverse Events in Targeted Radionuclide Therapy.
1/5 보강
Targeted radionuclide therapy (TRT) plays an important role in management of oncology patients, particularly those with thyroid cancer, prostate cancer, or neuroendocrine tumor.
APA
Guja KE, Wu J, et al. (2025). Adverse Events in Targeted Radionuclide Therapy.. Radiographics : a review publication of the Radiological Society of North America, Inc, 45(9), e240143. https://doi.org/10.1148/rg.240143
MLA
Guja KE, et al.. "Adverse Events in Targeted Radionuclide Therapy.." Radiographics : a review publication of the Radiological Society of North America, Inc, vol. 45, no. 9, 2025, pp. e240143.
PMID
40839540 ↗
Abstract 한글 요약
Targeted radionuclide therapy (TRT) plays an important role in management of oncology patients, particularly those with thyroid cancer, prostate cancer, or neuroendocrine tumor. Use of TRTs has expanded rapidly in recent years, with approval of new agents and indications. The number of ongoing TRT clinical trials suggests that this trend is likely to continue in the future. Adequate knowledge of potential adverse events and their management is essential for treating physicians to optimize outcomes in patients undergoing TRT. The authors review adverse events that may occur in TRT; their clinical manifestations, incidence, risk factors, and management; and strategies to prevent or decrease their risk of occurrence. RSNA, 2025.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.